Virtus ETF Advisers’s ProQR Therapeutics PRQR Stock Holding History

Virtus ETF Advisers’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-22,938	Closed	-$132K	–	499
2019 Q3	$132K	Sell	22,938 -1,278	-5%	-$10.2K	0.03%	279
2019 Q2	$220K	Buy	24,216 +9,291	+62%	+$110K	0.05%	282
2019 Q1	$207K	Sell	14,925 -1,757	-11%	-$26.2K	0.44%	88
2018 Q4	$263K	Buy	+16,682	New	+$306K	0.04%	153

Other funds holding PRQR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Virtus ETF Advisers's PRQR Position: Q4 2019 in Review

Virtus ETF Advisers sold out of ProQR Therapeutics (PRQR) in Q4 2019, closing a stake of 22,938 shares — an estimated $132K sold.

Virtus ETF Advisers first reported a position in PRQR in Q4 2018 and held it in 4 quarters. The position peaked at $263K in Q4 2018. 51 funds tracked by Wall St. Rank hold PRQR as of Q4 2019.

Virtus ETF Advisers reported no remaining ProQR Therapeutics position as of Q4 2019 after selling out during the quarter.
Virtus ETF Advisers sold 22,938 ProQR Therapeutics shares in Q4 2019, an estimated $132K.
Virtus ETF Advisers first reported a position in ProQR Therapeutics in Q4 2018 and held it in 4 quarters.
Virtus ETF Advisers's ProQR Therapeutics position peaked at $263K in Q4 2018.
51 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2019.

Based on Virtus ETF Advisers's 13F filing for Q4 2019, filed 13 Feb 2020.